Trial
NCT02906332
Pembrolizumab + Lenalidomide Post Autologous Stem Cell Transplant (ASCT) in High-risk Multiple Myeloma (MM)
Phase IITERMINATEDREGULATORYConfidence: HIGH
Sponsor
Hackensack Meridian Health
Collaborators
—
Condition
Multiple Myeloma
Intervention
Pembrolizumab
Why stopped
FDA Hold Due to Updated Risks
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-08-22